Outcome after non-myeloablative stem cell transplantation for chronic lymphocytic leukemia (CLL). Adapted from Sorrer et al.47
| . | All (n= 64) . | Related (n= 44) . | Unrelated (n= 20) . |
|---|---|---|---|
| Age, years (range) | 56 (44–69) | 55 (44–68) | 58 (49–69) |
| Fludarabine refractory | 55 | 37 | 18 |
| Graft failure | 3 | 1 | 2 |
| Acute graft-versus-host disease | |||
| Grade 2 | 26 | 19 | 7 |
| Grade 3 | 11 | 6 | 5 |
| Grade 4 | 1 | 1 | 0 |
| Chronic extensive | 31 | 19 | 12 |
| Relapse at 2 years | 26% | 34% | 5% |
| . | All (n= 64) . | Related (n= 44) . | Unrelated (n= 20) . |
|---|---|---|---|
| Age, years (range) | 56 (44–69) | 55 (44–68) | 58 (49–69) |
| Fludarabine refractory | 55 | 37 | 18 |
| Graft failure | 3 | 1 | 2 |
| Acute graft-versus-host disease | |||
| Grade 2 | 26 | 19 | 7 |
| Grade 3 | 11 | 6 | 5 |
| Grade 4 | 1 | 1 | 0 |
| Chronic extensive | 31 | 19 | 12 |
| Relapse at 2 years | 26% | 34% | 5% |